膵島ミトコンドリアを標的とした分子送達技術の開発及び糖尿病治療への展開

書誌事項

タイトル別名
  • A Nanocarrier System for Mitochondrial Delivery Targeted to a Pancreatic Beta Cell
  • Symposium Review 膵島ミトコンドリアを標的とした分子送達技術の開発及び糖尿病治療への展開
  • Symposium Review スイトウ ミトコンドリア オ ヒョウテキ ト シタ ブンシ ソウタツ ギジュツ ノ カイハツ オヨビ トウニョウビョウ チリョウ エ ノ テンカイ

この論文をさがす

抄録

<p>The destruction of β cells of pancreatic islets results in a reduced level of insulin secretion, thus resulting in the onset of diabetes. Diabetes caused by such a decrease in insulin secretion has been reported to be associated with mitochondrial dysfunction. Because of this, mitochondrial therapy would be expected to be a useful and productive strategy for the treatment of this disease. We previously reported the development of a MITO-Porter, a liposome-based nanocarrier that permits macromolecular cargos to be delivered into mitochondria via membrane fusion. In this presentation, we present our current findings on the development of a mitochondrial nanocarrier system aimed at the development of a novel method for treating and preventing diabetes. The system includes “a nanocarrier system for nucleic acids targeted to pancreatic β cells”, and “an in vivo system for the delivery of nucleic acids targeting the pancreas”. In this presentation, we propose the use of a “mitochondrial nanocarrier system” as a novel method for the treatment and prevention of diabetes, and discuss the contribution of mitochondrial nanocarrier systems to innovative drug development.</p>

収録刊行物

  • 薬学雑誌

    薬学雑誌 139 (1), 41-45, 2019-01-01

    公益社団法人 日本薬学会

参考文献 (10)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報

問題の指摘

ページトップへ